aDC1 vaccine / Roswell Park, University of Pittsburgh 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  aDC1 vaccine / Roswell Park, University of Pittsburgh
    Journal:  Effects of Injectable Solutions on the Quality of Monocyte-Derived Dendritic Cells for Immunotherapy. (Pubmed Central) -  Jul 4, 2024   
    Alpha-type-1-polarized dendritic cells (aDC1s) have been shown to induce type-1 immunity with a high capacity to produce interleukin-12p70 (IL-12p70)...Cellular morphology was observed by electron microscopy, and the production of IL-12p70 by aDC1s was evaluated by ELISA. Compared with normal saline, Ringer's lactate solution was more effective at maintaining DC viability for up to 8?hr of incubation at 4 or 22
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
    Phase classification, Combination therapy:  Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov) -  Jun 13, 2024   
    P2,  N=42, Recruiting, 
    Compared with normal saline, Ringer's lactate solution was more effective at maintaining DC viability for up to 8?hr of incubation at 4 or 22 Phase classification: P2a --> P2
  • ||||||||||  aDC1 vaccine / Roswell Park, University of Pittsburgh
    Activating anti-MDS immunity with polarized dendritic cell vaccines (Section 4) -  Mar 5, 2024 - Abstract #AACR2024AACR_9441;    
    We hypothesized that restoration of this population using a novel DC vaccination approach - alpha-type-1 polarized dendritic cells (?DC1) - might compensate for this deficiency and restore immunity...To date, our results suggest that generation of MDS patient-derived ?DC1 cells is feasible and additional work is being performed to fully characterize their ability to activate anti-MDS immune responses. Since ?DC1s have an established safety profile in patients with solid tumors, we anticipate that we will be able to rapidly translate our results to the clinic.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), aDC1 vaccine / Roswell Park, University of Pittsburgh
    Trial completion date, Trial primary completion date, Metastases:  Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) -  Aug 1, 2023   
    P2,  N=19, Not yet recruiting, 
    This work, overall, provides a foundation to further interrogate immune-mediated mechanisms of protection in order to help devise efficacious ?DC1-based strategies for patients with CRC. Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
    Enrollment open, Combination therapy:  Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov) -  Jun 22, 2023   
    P2a,  N=42, Recruiting, 
    Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025 Not yet recruiting --> Recruiting
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
    Trial initiation date, Combination therapy:  Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov) -  Jul 12, 2022   
    P2a,  N=42, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Jun 2022 --> Dec 2022
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
    Trial initiation date, Combination therapy:  Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov) -  Feb 4, 2022   
    P2a,  N=42, Not yet recruiting, 
    Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024 Initiation date: Jan 2022 --> Jun 2022
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
    New P2a trial, Combination therapy:  Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov) -  Nov 18, 2021   
    P2a,  N=42, Not yet recruiting, 
  • ||||||||||  aDC1 vaccine / Roswell Park, University of Pittsburgh
    Trial completion date, Trial primary completion date, Metastases:  Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov) -  Feb 11, 2021   
    P1/2,  N=25, Suspended, 
    Trial completion date: May 2024 --> Sep 2023 Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2022 --> May 2023
  • ||||||||||  aDC1 vaccine / Roswell Park, University of Pittsburgh
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov) -  Feb 24, 2020   
    P1/2,  N=25, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Oct 2019 Active, not recruiting --> Recruiting | N=13 --> 25 | Trial completion date: Dec 2020 --> May 2023 | Trial primary completion date: Dec 2019 --> May 2022
  • ||||||||||  aDC1 vaccine / Roswell Park, University of Pittsburgh
    Enrollment closed, Enrollment change, Metastases:  Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov) -  Jan 29, 2020   
    P1/2,  N=13, Active, not recruiting, 
    Active, not recruiting --> Recruiting | N=13 --> 25 | Trial completion date: Dec 2020 --> May 2023 | Trial primary completion date: Dec 2019 --> May 2022 Recruiting --> Active, not recruiting | N=40 --> 13